<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00229775</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCID-3913</org_study_id>
    <secondary_id>U30/CCU317876-01</secondary_id>
    <nct_id>NCT00229775</nct_id>
  </id_info>
  <brief_title>Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines</brief_title>
  <official_title>Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health, Philippines</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether artemether + lumefantrine is as effective&#xD;
      as chloroquine + sulfadoxine pyrimethamine in the treatment of uncomplicated Plasmodium&#xD;
      falciparum malaria&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: In the Philippines, close to 11 million people in 65 provinces are at risk for&#xD;
      acquiring malaria infections. It is still one of the ten leading causes of morbidity&#xD;
      nationwide. Each day, roughly 150-200 people fall ill with malaria. In the past 40 years, the&#xD;
      mortality rate stabilized at around 2/100,000 population. Of those people who have malaria,&#xD;
      approximately 1% die per year. Malaria remains one of the major causes of death in provinces&#xD;
      such as Palawan, Isabela, Tawi-tawi, Sulu and Butuan City. Approximately 70% of all malaria&#xD;
      in the Philippines is Plasmodium falciparum with the remaining species being P. vivax.&#xD;
&#xD;
      Recently the Department of Health (DOH) instituted a change in the national antimalarial drug&#xD;
      guidelines changing from using chloroquine (CQ) and sulfadoxine pyrimethamine (SP)&#xD;
      monotherapy as first and second line drugs, respectively, to a combined chloroquine plus&#xD;
      sulfadoxine-pyrimethamine as first-line treatment, and artemether-lumefantrine (Coartem) as&#xD;
      second line treatment. This change was made due to increasing levels of drug resistance to&#xD;
      the previous first and second-line therapies. In order to have an improved understanding of&#xD;
      the trends of antimalarial drug resistance in the Philippines, the DOH is initiating a&#xD;
      sentinel surveillance system for monitoring of antimalarial drug resistance. Three sites have&#xD;
      been selected to be representative of the country.&#xD;
&#xD;
      Objective: To establish a sentinel surveillance system to assess the efficacy of chloroquine&#xD;
      plus sulfadoxine-pyrimethamine versus artemether + lumefantrine for the treatment of&#xD;
      uncomplicated P. falciparum infections in three areas of the Republic of the Philippines.&#xD;
&#xD;
      Methods: An in vivo antimalarial drug efficacy trial will be conducted in three areas of the&#xD;
      Philippines. Subjects &gt; 6 months of age with parasitologically confirmed, uncomplicated P.&#xD;
      falciparum infections will be recruited. Patients will be treated with single dose SP (25&#xD;
      mg/kg of the sulfadoxine component in a single dose) plus CQ (25 mg/kg over three days) or&#xD;
      artemether + lumefantrine (twice daily) over 3 days. Patients will be randomly assigned one&#xD;
      of the two drugs regimens. Clinical and parasitological parameters will be monitored over a&#xD;
      28-day follow-up period to evaluate drug efficacy. Results from this study will be used to&#xD;
      assist the DOH in assessing their national malaria treatment policy for P. falciparum&#xD;
      malaria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin levels</measure>
  </secondary_outcome>
  <enrollment type="Actual">560</enrollment>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Weight &gt; 10 kg;&#xD;
&#xD;
          2. Documented fever (axillary temperature &gt;37.5oC) and/or a history of fever during the&#xD;
             previous 24 hours in the absence of another obvious cause of fever (such as pneumonia,&#xD;
             measles, otitis media);&#xD;
&#xD;
          3. Monoinfection with P. falciparum between 1,000 and 100,000 asexual parasites/µl as&#xD;
             determined by microscopic examination of thick, or thick and thin peripheral blood&#xD;
             smears;&#xD;
&#xD;
          4. Informed consent from the patient or parent/guardian (in the case of children),assent&#xD;
             from child (ages 8 -17 years inclusive);&#xD;
&#xD;
          5. Willingness on the part of the patient to return to the clinic for regular check-ups&#xD;
             during the 28-day follow-up period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Danger signs: unable to drink or breastfeed; vomiting (more than twice in the previous&#xD;
        24 hours); recent history of convulsions (one or more in the previous 24 hours); impaired&#xD;
        consciousness; unable to sit or stand; 2. Severe Manifestations of P. falciparum malaria in&#xD;
        adults and children (World Health Organization criteria)&#xD;
&#xD;
          1. Prostration (inability to sit unassisted [children], extreme weakness [adults])&#xD;
&#xD;
          2. Impaired consciousness (Blantyre coma scale [children], Glascow coma scale [adults])&#xD;
&#xD;
          3. Respiratory distress (sustained nasal flaring, indrawing, Kussmaul breathing)&#xD;
&#xD;
          4. Multiple convulsions (³2 convulsions/24 hour period)&#xD;
&#xD;
          5. Circulatory collapse (hypotension and poor perfusion)&#xD;
&#xD;
          6. Pulmonary edema&#xD;
&#xD;
          7. Abnormal bleeding&#xD;
&#xD;
          8. Jaundice&#xD;
&#xD;
          9. Hemoglobinuria&#xD;
&#xD;
         10. Severe anemia (Hb &lt; 5 gm/dL)&#xD;
&#xD;
         11. Hypoglycemia (blood glucose &lt; 2.2 mmol/L [&lt;40 mg/dL])&#xD;
&#xD;
         12. Acidosis (bicarbonate &lt;15 mmol/L)&#xD;
&#xD;
         13. Hyperparisitemia (level varies with endemicity)&#xD;
&#xD;
         14. Renal impairment (urine output &lt; 12 mL/kg/24 hours) 3. Other underlying chronic or&#xD;
             severe diseases (e.g., cardiac, renal, hepatic diseases, HIV/AIDS, malnutrition); 4.&#xD;
             History of hypersensitivity reactions to any of the drugs being tested or used as&#xD;
             alternative treatment: sulfonamides, chloroquine, artemisinins, artemether,&#xD;
             lumefantrine, quinine or tetracycline/clindamycin; 4. Pregnancy (history of pregnancy&#xD;
             or a positive urine pregnancy test); 5. Women who are breast feeding children less&#xD;
             than 8 weeks of age. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorin Bustos, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>RITM, DOH, Philippines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kalinga Health Center</name>
      <address>
        <city>Tabuk</city>
        <state>Kalinga Province</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davao Health Center</name>
      <address>
        <city>Davao City</city>
        <state>Mindinao</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palawan Health Center</name>
      <address>
        <city>Puerto Princesa</city>
        <state>Palawan</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 28, 2005</study_first_submitted>
  <study_first_submitted_qc>September 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2005</study_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmodium falciparum malaria</keyword>
  <keyword>malaria</keyword>
  <keyword>artemether lumafantrine</keyword>
  <keyword>chloroquine</keyword>
  <keyword>sulfadoxine pyrimethamine</keyword>
  <keyword>Coartem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

